Brainstorm Cell Therapeutics Inc

Brainstorm Cell Therapeutics Inc. is a biotechnology company that develops and commercializes autologous cellular therapies for neurodegenerative diseases. Its proprietary NurOwn cell therapy platform uses cell culture methods to induce autologous bone marrow-derived mesenchymal stem cells to secrete high levels of neurotrophic factors, modulate neuroinflammatory and neurodegenerative disease processes, promote neuronal survival, and enhance neurological function. NurOwn has completed a Phase IIIb clinical trial for amyotrophic lateral sclerosis, a Phase II clinical trial for progressive multiple sclerosis, and is also being developed for Alzheimer's disease and other neurodegenerative diseases. The company was incorporated in 2000 and is headquartered in New York, New York.